Abstract: A self-piercing rivet includes a head, an outer cylindrical part extending from the head and formed in a cylindrical shape, and an inner cylindrical part extending from the head, provided spaced apart inside the outer cylindrical part, and formed in a cylindrical shape. In the manufacturing method for a fastening structure, a self-piercing rivet is driven into an overlapping part of a first fastened member and a second fastened member to fasten the first fastened member and the second fastened member.

Abstract: An object of the present invention is to provide a novel lactic acid bacterium-containing tablet. According to the present invention, there is provided a lactic acid bacterium-containing tablet comprising: (A) a lactic acid bacterium; (B) an excipient; and (C) a lubricant, wherein a content of the (C) in the tablet is less than 10 mass %, and a mass per tablet is 200 mg or more. The (B) preferably contains at least (B1) hydroxypropyl cellulose and/or (B2) crystalline cellulose or ?-cyclodextrin. The lactic acid bacterium is preferably a bacterium of the genus Lactococcus. According to the present invention, there is provided a lactic acid bacterium-containing tablet having high ingestion efficiency and excellent hardness.

Abstract: A self-piercing rivet includes a head, an outer cylindrical part extending from the head and formed in a cylindrical shape, and an inner cylindrical part extending from the head, provided spaced apart inside the outer cylindrical part, and formed in a cylindrical shape. In the manufacturing method for a fastening structure, a self-piercing rivet is driven into an overlapping part of a first fastened member and a second fastened member to fasten the first fastened member and the second fastened member.

Abstract: In a casting step, a first member is cast by die casting. In the driving step after the casting step, a self-piercing rivet is driven into, from a second member side, an overlapping part in which the second member overlaps the first member, while heat from casting remains in the first member. As a result, the self-piercing rivet is driven into the first member in a state that the ductility is higher than that at the normal temperature. Therefore, the first member is less likely to crack during the driving step.

Abstract: A thickened part is formed in the first member. The thickened part has a protruded part that is convex on one side in the thickness direction of the first member, so that the thick portion is set thicker than the general portion as the other portion. At least a part of the second member overlaps a part of the first member that includes the thickened part from another side of the first member in the plate thickness direction, and the self-piercing rivet is driven into a fastening overlapped part that is a part that the second member overlaps the thickened part from a second member side, so as to fasten the first member and the second member.

Abstract: A thickened part is formed in the first member. The thickened part has a protruded part that is convex on one side in the thickness direction of the first member, so that the thick portion is set thicker than the general portion as the other portion. At least a part of the second member overlaps a part of the first member that includes the thickened part from another side of the first member in the plate thickness direction, and the self-piercing rivet is driven into a fastening overlapped part that is a part that the second member overlaps the thickened part from a second member side, so as to fasten the first member and the second member.

Abstract: A vehicle skeleton structure, including: a die-cast skeleton body formed integrally and including a floor part configuring a vehicle cabin floor portion and a side member extending from the floor part towards a vehicle front or a vehicle rear; a transverse concave bead, the transverse concave bead being formed at a leading end side of the side member in the skeleton body, and the transverse concave bead extending in at least one of a vehicle width direction or a vehicle vertical direction; and a longitudinal concave bead, the longitudinal concave bead being formed at a base end side of the side member in the skeleton body, and the longitudinal concave bead extending in a vehicle front-rear direction.

Abstract: A vehicle skeleton structure, including: a die-cast skeleton body formed integrally and including a floor part configuring a vehicle cabin floor portion and a side member disposed at both sides, in a vehicle width direction, of the floor part and extending in a vehicle front-rear direction; and a severance origin point, the severance origin point being formed at the skeleton body, and the severance origin point configuring a starting point when at least a part of the side member is severed.

Abstract: A cell for electrochemical measurement is a cell for electrochemical measurement used for measurement by an electron beam that passes through an observation window, a MEMS chip for observation which includes a laminate including an electron-transmissive thin film and a substrate and in which a working electrode and a counter electrode are provided on a thin film and an MEMS chip for sealing which is a laminate including an electron-transmissive thin film and a substrate are disposed apart from each other, and there are areas in both laminates in which the substrates are not present, and an observation window including the thin film is formed in the areas, and the working electrode overlaps the observation window in both laminates and has a plurality of through-holes on an observation window in a direction in which an electron beam passes.

Abstract: A cell for electrochemical measurement is a cell for electrochemical measurement used for measurement by an electron beam that passes through an observation window, a MEMS chip for observation which includes a laminate including an electron-transmissive thin film and a substrate and in which a working electrode and a counter electrode are provided on a thin film and an MEMS chip for sealing which is a laminate including an electron-transmissive thin film and a substrate are disposed apart from each other, and there are areas in both laminates in which the substrates are not present, and an observation window including the thin film is formed in the areas, and the working electrode overlaps the observation window in both laminates and has a plurality of through-holes on an observation window in a direction in which an electron beam passes.

Abstract: Provided is a rare-earth magnet containing no heavy rare-earth metals such as Dy or Tb in a grain boundary phase, has a modifying alloy for increasing coercivity (in particular, coercivity under a high-temperature atmosphere) infiltrated thereinto at lower temperature than in the conventional rare-earth magnets, has high coercivity, and has relatively high magnetizability, and a production method therefor. The rare-earth magnet RM includes a RE-Fe—B-based main phase MP with a nanocrystalline structure (where RE is at least one of Nd or Pr) and a grain boundary phase BP around the main phase, the grain boundary phase containing a RE-X alloy (where X is a metallic element other than heavy rare-earth elements). Crystal grains of the main phase MP are oriented along the anisotropy axis, and each crystal grain of the main phase, when viewed from a direction perpendicular to the anisotropy axis, has a plane that is quadrilateral in shape or has a close shape thereto.

Abstract: A conveyor apparatus for conveying a moving body along a conveyance path, the conveyor apparatus comprising: a frame body to which a pair of roller members that rolls along the conveyance path are attached; a pair of guide rails on which the roller members travel; cables for connecting various devices; and a support member having a support surface to support the cables, wherein each of the guide rails comprises: a traveling portion on which the roller members travel, and a side wall portion extending from the traveling portion, wherein the side wall portion of one of the guide rails and the side wall portion of the other one of the guide rails are arranged separately from each other, and wherein the cables are housed in a space defined by the support surface and the respective side wall portions.

Abstract: An electrode catalyst for a fuel cell includes: a carbon support having a crystallite diameter of 2.0 nm to 3.5 nm at a carbon (002) plane, and having a specific surface area of 400 m2/g to 700 m2/g; and a catalyst metal containing platinum and a platinum alloy that are supported on the carbon support, and having a crystallite diameter of 2.7 nm to 5.0 nm at a platinum (220) plane. A ratio of a peak height of a spectrum of the platinum alloy in a form of an intermetallic compound with respect to a peak height of a spectrum of platinum is 0.03 to 0.08. The spectrum of the platinum alloy and the spectrum of platinum are measured through X-ray diffraction.

Abstract: [Problem] Provided is a compound having a positive allosteric modulating activity (PAM activity) on an ?7 nicotinic acetylcholine receptor (?7 nACh receptor). [Means for Solution] The present inventors have studied on a PAM activity on an ?7 nACh receptor, and they have found that a tetrahydrooxepinopyridine compound has a PAM activity on an ?7 nACh receptor, thereby completing the present invention. The tetrahydrooxepinopyridine compound of the present invention has a PAM activity on an ?7 nACh receptor and can be expected as an agent for preventing or treating dementia, cognitive impairment, schizophrenia, Alzheimer's disease, CIAS, negative symptoms of schizophrenia, inflammatory diseases, or pain.

Abstract: [Problem] Provided is a compound having a positive allosteric modulating activity (PAM activity) on an ?7 nicotinic acetylcholine receptor (?7 nACh receptor). [Means for Solution] The present inventors have studied on a PAM activity on an ?7 nACh receptor, and they have found that a tetrahydrooxepinopyridine compound has a PAM activity on an ?7 nACh receptor, thereby completing the present invention. The tetrahydrooxepinopyridine compound of the present invention has a PAM activity on an ?7 nACh receptor and can be expected as an agent for preventing or treating dementia, cognitive impairment, schizophrenia, Alzheimer's disease, CIAS, negative symptoms of schizophrenia, inflammatory diseases, or pain.

Abstract: Provided is a rare-earth magnet containing no heavy rare-earth metals such as Dy or Tb in a grain boundary phase, has a modifying alloy for increasing coercivity (in particular, coercivity under a high-temperature atmosphere) infiltrated thereinto at lower temperature than in the conventional rare-earth magnets, has high coercivity, and has relatively high magnetizability, and a production method therefor. The rare-earth magnet RM includes a RE-Fe—B-based main phase MP with a nanocrystalline structure (where RE is at least one of Nd or Pr) and a grain boundary phase BP around the main phase, the grain boundary phase containing a RE-X alloy (where X is a metallic element other than heavy rare-earth elements). Crystal grains of the main phase MP are oriented along the anisotropy axis, and each crystal grain of the main phase, when viewed from a direction perpendicular to the anisotropy axis, has a plane that is quadrilateral in shape or has a close shape thereto.

Abstract: [PROBLEMS] Provided is a compound which has an antagonistic action on a muscarinic M3 receptor and is useful as an active ingredient of a prophylactic and/or therapeutic agent for an inflammatory disease such as a chronic obstructive pulmonary disease (COPD), asthma and the like. [MEANS For SOLVING PROBLEMS] The present inventors have made studies on a compound having an antagonistic action on the binding of a muscarinic M3 receptor, and they have found that an aza-bridged-ring compound or a salt thereof has an antagonistic action on the binding of a muscarinic M3 receptor, thereby completing the present invention. The aza-bridged-ring compound of the present invention has an antagonistic action on the binding of a muscarinic M3 receptor, and can be used as a prophylactic and/or therapeutic agent for an inflammatory disease such as a chronic obstructive pulmonary disease (COPD), asthma and the like.

Abstract: A compound which may be used for the prevention or treatment of respiratory diseases in which STAT 6 is concerned, particularly asthma, chronic obstructive pulmonary disease and the like is provided. A pyrimidine derivative or a salt thereof, which has an arylamino or arylethylamino group which may be substituted with a specified substituent, at the 2-position, amino group substituted with benzyl group or the like, at the 4-position, and carbamoyl group which may be substituted, at the 5-position, is provided.

Abstract: A compound which may be used for the prevention or treatment of respiratory diseases in which STAT 6 is concerned, particularly asthma, chronic obstructive pulmonary disease and the like is provided. A pyrimidine derivative or a salt thereof, which has an arylamino or arylethylamino group which may be substituted with a specified substituent, at the 2-position, amino group substituted with benzyl group or the like, at the 4-position, and carbamoyl group which may be substituted, at the 5-position, is provided.

Abstract: Provided is a compound which is useful as an active ingredient for a pharmaceutical having a PKC? inhibition activity, particularly a pharmaceutical composition for inhibiting acute rejection occurring in transplantation. The present inventors have conducted extensive studies on a compound having a PKC? inhibition activity, and as a result, they have found that a compound having a structure such as aralkyl and the like on an amino group at the 2-position and also having a structure such as an adamantylalkyl group and the like on an amino group at the 4-position of 2,4-diaminopyrimidine, or a salt thereof has an excellent PKC? inhibition activity, thereby completing the present invention. The 2,4-diaminopyrimidine compound of the present invention can be used as a PKC? inhibitor or an inhibitor of acute rejection occurring in transplantation.